pancreatic exocrine insufficiency

pancreatic exocrine insufficiency,

n low levels of pancreatic proteases and lipases in the small intestine resulting in improper digestion of carbohydrate, fiber, and protein foods, eventually leading to malabsorption.
References in periodicals archive ?
Pancrelipase: An evidence-based review of its use for treating pancreatic exocrine insufficiency.
Patients with chronic pancreatitis frequently present with pancreatic exocrine insufficiency combined with a persistently low duodenal pH in the postprandial period.
In pancreatic exocrine insufficiency (PEI), defined "as a reduction in pancreatic enzyme activity in the intestinal lumen to a level that is below the threshold required to maintain normal digestion," (36) it has been established that steatorrhea does not occur until pancreatic lipase output is reduced to 5%-10% of normal output.
Abbott Japan received approval to manufacture and market Lipacreon in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI) on April 22 of this year, with the drug being registered on the National Health Insurance Drug Price List on July 19.
Abbott Japan received approval to manufacture and market Lipacreon in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI) on 22 April 2011, with the drug being registered on the National Health Insurance Drug Price List on 19 July.
The majority of CF patients have pancreatic exocrine insufficiency, even in early infancy, which, if untreated, leads to fat malabsorption and malnutrition (5).
TSE: 4523) announced today that they have received approval to market the pancreatic enzyme replacement drug Lipacreon(R)(pancrelipase) in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI).
Indirect PFTs measure the consequences of pancreatic exocrine insufficiency and are more widely available than direct PFTs.
Tokyo, Dec 24, 2009 - (JCN Newswire) - A New Drug Application for the pancreatic enzyme replacement therapy agent for pancreatic exocrine insufficiency, SA-001 (API name: Pancrelipase) that Solvay Seiyaku K.